Search

Choline

It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.

Avibactam

As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options. … This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract

Ethoxzolamide

Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.

Strontium chloride

This kind of barrier protection for tooth hypersensitivity has, however, been superseded by other toothpaste formulations and ingredients designed to be nerve calming agents instead [A33167, A33168].

Ixazomib

[L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.

Chromic nitrate

ALTU-135

ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA).

Almonertinib

[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.

Carfentanil

It is marketed under the trade name Wildnil as a general anaesthetic agent for large animals. … Carfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen.

Vamorolone

[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.